BiofarmBSE:BIO +0.37%69 Net Margin % is 35.17% as of Mar. 2026, which is 38% above its 10-year median of 25.43. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 957 Drug Manufacturers companies, Biofarm ranks better than 95.72% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Biofarm's Net Income for the
three
months ended in Mar. 2026 was lei32.5 Mil. Biofarm's Revenue for the
three
months ended in Mar. 2026 was lei92.5 Mil. Therefore, Biofarm's net margin for the quarter that ended in Mar. 2026 was 35.17%.
The historical rank and industry rank for Biofarm's Net Margin % or its related term are showing as below:
BSE:BIO'
s Net Margin % Range Over the Past 10 Years
Min: 19.38 Med: 25.43 Max: 31.84
Current: 31.84
BSE:BIO's Net Margin % is ranked better than 95.72% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs BSE:BIO: 31.84
Biofarm (BSE:BIO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biofarm Net Margin % Related Terms
Biofarm Net Margin % Historical Data
* Premium members only.
The historical data trend for Biofarm's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:BIO vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biofarm's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (BSE:BIO) has a Net Margin % of 35.17% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Biofarm and its competitors. This is 38% above median its historical median of 25.43. Over the past decade, Biofarm's Net Margin % has ranged from 19.38 to 31.84. According to the industry distribution chart, Biofarm ranks #41 out of 957 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Biofarm's Net Margin % too high?
Biofarm's current Net Margin % of 35.17% is 38% above median its 10-year median of 25.43. Over the past 10 years, this metric has ranged from a low of 19.38 to a high of 31.84. The Drug Manufacturers industry median Net Margin % is 5.58. Biofarm's value of 35.17% is 530.3% above this industry median. Based on the distribution chart, Biofarm ranks #41 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #41 out of 957 companies for Net Margin %. This places Biofarm in the top 4% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.58. Biofarm's value of 35.17% is 530.3% above this benchmark. Historically, Biofarm's own Net Margin % has ranged from 19.38 to 31.84 over the past decade. While the company's 10-year median is 25.43 vs. the industry median of 5.58, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current Net Margin % of 35.17% is 530.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current Net Margin % is 35.17%, which is 38% above median its own 10-year median of 25.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.37 — trading 57.5% above its estimated fair value. The current Net Margin % is 35.17%, which is 38% above median its 10-year median of 25.43 and 530.3% above the Drug Manufacturers industry median of 5.58. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Net Margin % is 35.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (BSE:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei1.37 is trading 57.5% above its estimated GF Value™ of lei0.87.
GuruFocus considers Biofarm to be Significantly Overvalued.
Key valuation signals for BSE:BIO:
Net Margin %: 35.17% (38% above median its 10-year median of 25.43)
GF Value™: lei0.87 vs. price of lei1.37 (57.5% above fair value)
Industry Position: 530.3% above the Drug Manufacturers median (#41 of 957)
No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for BSE:BIO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:BIO has been successfully added to your 
